Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of the drug leflutrozole on semen quality in men aged 18 to 49 years with low testosterone levels. This phase 2 clinical trial aims to find out whether leflutrozole can improve semen quality and what side effects participants may experience compared to a placebo. The trial is sponsored by ReproNovo Aps and focuses on testicular function and hormone levels. Participants will be randomly assigned to receive one of three doses of leflutrozole 0.05 mg, 0.1 mg, or 0.3 mg or a placebo. The medication is taken orally once a week for 16 weeks. The study is double-blind, meaning neither the participants nor the researchers know who receives the drug or placebo. Checkups and tests occur every 4 weeks during the treatment period. Men in the trial will provide semen samples to measure sperm count, motility, and other quality markers. Blood tests will monitor hormone levels such as testosterone and estradiol, as well as safety markers including prostate-specific antigen and ECG readings. Questionnaires will assess changes in libido and energy. Researchers will track adverse events throughout the 16 weeks to evaluate safety and effectiveness.
Actively Recruiting
This research aims to evaluate the effects of different doses of vosoritide and compare the therapeutic dose of vosoritide to human growth hormone hGH in children diagnosed with idiopathic short stature ISS. The study is a Phase 2, randomized, controlled trial that seeks to understand how these treatments influence growth in affected children. Participants will first undergo a minimum 6-month observation period to assess their baseline growth. Then, those assigned to the vosoritide and placebo groups will receive randomized treatment for at least 6 months, with placebo limited to a maximum of 6 months. After this, open-label vosoritide treatment will continue until participants reach near-final adult height or at least 16 years for females and 18 years for males, whichever is later. Participants randomized to the hGH group will receive open-label hGH treatment for a minimum of 4 years. Study treatments involve daily injections. Throughout the study, participants will attend regular visits for clinical and imaging assessments, including evaluations of hips and lower extremities. Researchers will monitor safety concerns such as hypotension, fractures, and slipped capital femoral epiphysis, with oversight from an independent Data Monitoring Committee. The main outcomes measured include changes in annualized growth velocity at 6 months and height changes over 4 years. Follow-up assessments will continue as needed, including safety monitoring, until study completion, which could last up to 15 years.
Actively Recruiting
Researchers are conducting an observational study to collect baseline growth data in children diagnosed with Idiopathic Short Stature ISS. The study aims to better understand growth patterns by measuring various growth-related factors over time in this pediatric population aged between 2 and 16 years, with a focus on children experiencing significant short stature. This long-term study is sponsored by BioMarin Pharmaceutical to help characterize how children with ISS grow compared to typical growth standards. Participants will be observed without receiving any study treatments. Growth measurements such as annualized growth velocity, height Z-score, standing height, body mass index BMI, and BMI Z-score will be collected every six months. The study will also record medical events and explore relationships between genetic variants and growth velocity. This observational approach allows tracking changes over time without intervention. Families will be involved in regular assessments every six months for up to 15 years. These evaluations include physical growth measurements and monitoring of medical events related to short stature. Data from historic growth hormone hGH stimulation tests and treatment status will also be considered. The studys primary outcomes focus on changes in growth metrics, while secondary outcomes assess medical event rates and genetic associations. Participation requires ongoing cooperation for scheduled measurements and consent from parents or guardians.
Actively Recruiting
Healthy Volunteer
This research investigates patient preference and the safety and eye-related effectiveness of a new treatment method called Dextenza combined with an intracameral antibiotic and NSAID, compared to standard eye drop therapy after cataract surgery. The study involves patients undergoing surgery in both eyes and aims to control pain and inflammation following the procedures. Participants will be randomly assigned to receive either the experimental treatment or the standard topical therapy in their first eye surgery. The experimental group receives a Dextenza dexamethasone intracanalicular insert placed in the lower punctum during surgery, along with intracameral ketorolac and moxifloxacin administered during and after the procedure. The control group receives standard topical drops including moxifloxacin, ketorolac, and prednisolone acetate at scheduled intervals before and after surgery. Two weeks later, the second eye will be operated on and treated with the alternate treatment. During the study, participants will attend several visits for assessments including patient preference measured 28 days after the second eye surgery, ocular inflammation scores, post-operative pain ratings, visual acuity tests, physician evaluations of insertion, and monitoring for adverse events. These evaluations occur at various time points up to two months following the second surgery, enabling researchers to compare the treatments comprehensively and monitor safety and effectiveness over time.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.
Actively Recruiting
Researchers are observing patients with pancreatic cysts to assess the use of confocal laser endomicroscopy nCLE as an imaging biomarker for diagnosis. The study involves patients referred to academic centers for endoscopic ultrasound EUS evaluation of pancreatic cystic lesions PCL who meet specific criteria. The goal is to improve the accuracy of PCL diagnosis and risk stratification, particularly for intraductal papillary mucinous neoplasms IPMNs. Participants undergo EUS-guided nCLE imaging first, followed by EUS-guided fine needle aspiration FNA to collect cyst fluid. The fluid is analyzed for carcinoembryonic antigen CEA, cytology, and molecular markers as part of standard care. Based on multidisciplinary tumor board recommendations, some patients may proceed to surgery, where surgical histopathology acts as the gold standard for diagnosis. During the study, participants are evaluated using these imaging and fluid analysis procedures. Researchers measure the accuracy of diagnosis and risk stratification over 48 months, also assessing imaging quality. The study involves obtaining patient consent and collecting data from procedures and surgical outcomes when applicable, continuing until the study completion date in 2028.
Actively Recruiting
Researchers are studying the unique natural history of blood sugar control, insulin sensitivity, and beta-cell function in obese adolescents at risk for developing type 2 diabetes. This observational study aims to understand how these factors and their causes change as youth transition through puberty, providing important information that could help design future treatments and prevention strategies for youth-onset type 2 diabetes. The study will carefully examine a large group of young people at risk for type 2 diabetes using detailed biochemical, clinical, and psychosocial assessments. Participants aged 8 to 15 years who meet specific criteria related to obesity, puberty stage, and blood sugar levels will be observed over an average of 2.5 years. No treatments or medications are being tested instead, the study focuses on tracking natural changes and risk factors over time. Throughout the study, participants will undergo regular evaluations to monitor blood sugar control, beta-cell function, insulin sensitivity, and fatty acid metabolism. These measures will be collected along with clinical and psychosocial data to better understand the progression toward type 2 diabetes. The research team will review these outcomes continuously during the study period, aiming to improve knowledge about diabetes risk in youth and inform future care approaches.
Actively Recruiting
This research aims to develop and validate a single-gene Non-Invasive Prenatal Test sgNIPT to detect serious health conditions like cystic fibrosis, spinal muscular atrophy, sickle cell disease, and thalassemias in unborn babies. It focuses on pregnant people with higher risk pregnancies due to carrier status or affected conditions, including cases without reproductive partner screening. The study will gather blood samples and medical information from pregnant participants and, when applicable, their partners and newborns. Participants will undergo the investigational sgNIPT, which is designed for pregnant people whose fetus is at increased risk for a single-gene disorder. This includes situations where there is no partner screening, positive partner screening but no prenatal diagnostic testing, or ultrasound findings suggesting a single-gene disorder regardless of carrier status. The study will collect newborn cheek swabs and health data within six months after delivery as part of the research. During the study, participants will provide blood samples after nine weeks of pregnancy, and researchers will collect medical and genetic information from participants and their partners. Newborn health information and cheek swabs will be collected post-delivery to assess the tests performance. The primary outcome is the accuracy of the sgNIPT in detecting four main autosomal recessive disorders approximately two years after study launch, followed by evaluation of other single gene disorders about six months later. Participation involves consenting to these procedures and ongoing information sharing throughout the study period.
Actively Recruiting
This research registry collects prospective information on patients managing chronic pain caused by knee osteoarthritis OA or optimizing pain treatment for knee replacement surgery due to knee OA. It aims to gather data on various pain therapies used for OA, including cryo nerve block, radiofrequency ablation RFA, injections like corticosteroids, viscosupplementation, opioids, and other medications such as non-steroidal anti-inflammatory drugs NSAIDs. Participants receive different pain management treatments as part of their care for knee OA, which may include procedures like nerve blocks or injections, or undergo knee arthroplasty if needed. The registry monitors these therapies and treatments over time without assigning specific interventions since it is observational. Throughout the study, participants provide information through questionnaires and medication logs to track pain levels using scales like the Numeric Rating Scale NRS and Brief Pain Inventory-short form BPI-sf, functional status through knee outcome scores, quality of sleep, opioid use, adverse events, patient satisfaction, healthcare utilization, and other health-related quality of life measures. Data collection continues for up to 18 months to observe outcomes and treatment effects over time.
Actively Recruiting
Researchers are evaluating the combination of ladarixin and sotorasib in patients with advanced non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation. This phase III open-label study aims to determine the best dose of ladarixin to use with sotorasib and to assess how long patients live without their cancer progressing. The study focuses on patients who have not previously been treated with KRAS G12C inhibitors and have experienced progression after prior therapies. Participants will receive sotorasib once daily at an approved dose of 960 mg and ladarixin twice daily. In the phase I part, ladarixin dosing will be carefully increased to find the recommended dose for phase II, with close monitoring for side effects during 21-day treatment cycles. Phase II will use the recommended dose of ladarixin alongside sotorasib over similar 21-day cycles. All patients receive the same combination treatment. During the study, participants will undergo various assessments including laboratory tests to monitor blood counts and organ function, imaging scans to evaluate tumor response, and tracking of any side effects. The primary outcomes include measuring dose-limiting toxicities in the first treatment cycle and progression-free survival up to 36 months. Safety and treatment responses will be followed closely, with survival and adverse events monitored throughout the study duration.
1-10 of 16
1